Financial Data and Key Metrics Changes - The company reported consolidated revenues of $106.2 billion, an increase of 11% year-over-year, driven by broad-based growth across the business [21][28] - Adjusted earnings per diluted share increased 16% to $9.34, reflecting strong operational performance [22][28] - Operating profit rose 13% year-over-year to $1.7 billion, supported by increased demand for access solutions and strong growth in specialty distribution [22][28] Business Line Data and Key Metrics Changes - North American Pharmaceutical revenues increased by 9% to $88.3 billion, driven by higher prescription volumes and specialty product distribution strength [23][28] - Oncology and Multispecialty segment revenues surged 37% to $13 billion, with operating profit increasing 57% to $366 million, aided by provider growth and acquisitions [24][28] - Prescription Technology Solutions revenues grew by 9% to $1.5 billion, with operating profit rising 18% to $277 million, driven by demand for access solutions [25][28] Market Data and Key Metrics Changes - GLP-1 distribution revenues reached $14 billion, up $3 billion or 26% compared to the prior year, indicating strong market demand [23][28] - The company anticipates revenue growth of 12%-16% and operating profit growth of 13%-17% for fiscal 2026, reflecting sustained momentum across core businesses [28][29] Company Strategy and Development Direction - The company is focused on two strategic growth pillars: Oncology and Multispecialty, and Biopharma Services, aiming to leverage its scale and connectivity in the community space [7][9] - Investments are being made in technology and automation to enhance operational efficiency and improve patient access to medications [11][12] - The company is progressing with the separation of its Medical-Surgical business, targeting an IPO by the second half of calendar 2027 [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to extend momentum and execute against strategic priorities, highlighting a strong financial position and disciplined capital allocation [18][36] - The operating environment is viewed as navigable despite regulatory changes, with ongoing engagement with lawmakers to advocate for patient access and community care [68][69] Other Important Information - The company completed the divestiture of its Norwegian operations, marking the final step in its exit from Europe, which is expected to contribute approximately $1 billion in revenue for fiscal 2026 [20][28] - Free cash flow for the quarter was $1.1 billion, with a total of $9.6 billion for the trailing 12 months, demonstrating strong operational performance [26][27] Q&A Session Summary Question: Can you discuss the specific investments in technology and automation? - Management highlighted investments in AI and automation to improve workflows, resulting in increased productivity during the annual verification season [39][40] Question: What is the long-term opportunity to improve margins in the segment? - Management noted that half of the segment's revenue is related to third-party logistics, with ongoing automation expected to enhance margins [43][44] Question: Any nuances to consider for fiscal 2027 guidance? - Management indicated stable utilization trends and strong specialty distribution growth, with a focus on operational efficiency as positive indicators for future performance [50][51] Question: What is driving the margin improvement in Oncology and Multispecialty? - Management attributed margin improvements to provider additions and growth in specialty oncology products, with ongoing automation efforts expected to further enhance margins [55][57] Question: How is the company navigating regulatory changes? - Management expressed confidence in navigating the regulatory landscape, emphasizing constructive discussions with manufacturing partners regarding pricing strategies [68][69]

Financial Data and Key Metrics Changes - Revenue increased by 11% to $106.2 billion, driven by broad-based growth across the business and higher prescription volumes [19][25] - Adjusted earnings per diluted share rose by 16% to $9.34, reflecting strong operational performance [21][25] - Operating profit increased by 13% year-over-year to $1.7 billion, supported by demand for access solutions and specialty distribution [20][25] Business Line Data and Key Metrics Changes - North American pharmaceutical revenues grew by 9% to $88.3 billion, with GLP-1 distribution revenues reaching $14 billion, up 26% year-over-year [21][22] - Oncology and multispecialty segment revenues surged by 37% to $13 billion, with operating profit increasing by 57% to $366 million [22][23] - Prescription technology solutions segment revenues rose by 9% to $1.5 billion, with operating profit up 18% to $277 million [23] Market Data and Key Metrics Changes - The U.S. Oncology Network now includes approximately 3,400 providers, with significant contributions from the integration of Florida Cancer Specialists and PRISM Vision [6][8] - The company reported strong demand for biopharma services, adding over 50 new programs across 43 unique brands during the quarter [9][60] Company Strategy and Development Direction - The company is focused on oncology and multispecialty services, leveraging its scale and leadership to meet evolving market needs [6][8] - Investments are being made in technology and automation to enhance operational efficiency and improve patient access to medications [10][36] - The company is progressing with the separation of its medical-surgical business, aiming for an IPO by the second half of calendar 2027 [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain momentum and execute strategic priorities, raising full-year EPS guidance to $38.80-$39.20, reflecting 17%-19% growth [4][25] - The company anticipates revenue growth of 12%-16% and operating profit growth of 13%-17% for the full year, supported by strong third-quarter performance [25][26] Other Important Information - The company completed the divestiture of its Norwegian operations, marking the final step in its exit from Europe [18] - Free cash flow for the quarter was reported at $1.1 billion, with plans to repurchase approximately $2.5 billion of shares [24][32] Q&A Session Questions and Answers Question: Can you talk about the specific investments you're making in technology and automation? - Management highlighted investments in AI and automation to improve workflows, allowing employees to support more patients efficiently during the annual verification season [35][36] Question: How should we think about the longer-term opportunity to improve margins in that segment? - Management noted that operating margins have grown over 130 basis points year-over-year, with a focus on automating capabilities and services for biopharma partners [38] Question: What are the key drivers of growth in the North American pharmaceutical segment? - Management pointed to strong specialty distribution growth and operational efficiency gains as key drivers of growth in the segment [40][52]

Core Insights - Quest Diagnostics and Epic have announced a collaboration aimed at enhancing the laboratory testing experience for healthcare providers and patients in the United States [1][2][3] Group 1: Collaboration Details - The partnership will support Project Nova, a multi-year initiative by Quest to simplify and improve customer-facing processes, enhancing experiences for patients and providers across various EHR platforms [2][5] - Epic's Diagnostic Enterprise system will be integrated into Quest's national laboratory operations, including technologies like Aura, Beaker Laboratory, and MyChart [2][3] Group 2: Expected Benefits - Customers can expect faster and more convenient services, improved access to health insights, and quicker turnaround times for testing services [4][7] - The collaboration aims to streamline systems related to lab ordering, results reporting, and patient appointment scheduling, enhancing overall operational efficiency [7] Group 3: Leadership and Implementation - A cross-organization team experienced in large-scale implementations will oversee a phased rollout, ensuring a smooth transition for health systems and providers [5] - The focus will be on creating a comprehensive test list and improving patient engagement through MyChart [3][5]